Conference Coverage
Conference Coverage
First-in-class TYK inhibitor shows durable effect for psoriasis
“Deucravacitinib is very distinct from the other JAK inhibitors, and I think we are seeing this in the clinical studies.”
News
Ask about itch and joint pain in pediatric psoriasis patients, expert advises
Several studies have described an increased risk of metabolic syndrome in adolescents with pediatric psoriasis and now in prepubertal children...
Conference Coverage
Psoriatic arthritis health care costs continue to rise over time
In a database claims review, the average person with PsA had higher inpatient, outpatient, and pharmacy costs, compared with those with only...
Conference Coverage
Physicians question the future of TNF inhibitors for psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of...
Conference Coverage
COVID-19 vaccine hesitancy still weighs heavy for some rheumatic disease patients
ACR COVID-19 vaccine task force chair Dr. Jeffrey Curtis goes over the latest evidence about COVID-19 vaccination in patients with rheumatic and...
Conference Coverage
Patients on methotrexate show T-cell response to Pfizer vaccine
Despite poor antibody response to the mRNA COVID-19 vaccine, cellular immunity was generated in patients taking methotrexate, new research shows...
Conference Coverage
Study spanning 2 decades offers insights into pediatric psoriasis trends
The researchers did not find that obesity was a marker of psoriasis severity in the cohort.
Conference Coverage
Secukinumab provides clinical benefit in phase 3 juvenile arthritis trial
Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.
Conference Coverage
Risankizumab shows efficacy, tolerability in patients with PsA
More than half of participants receiving risankizumab achieved the primary endpoint of at least 20% improvement in ACR response criteria, compared...
Conference Coverage
GRAPPA refines recommendations on psoriatic disease treatment
Biosimilars, Janus kinase inhibitors, and interleukin-23 inhibitors will feature in the 2021 update.